文献速递白血病造血干细胞移植与细胞治疗

在儿童和年轻成人中按确定配方和剂量使用CD19 CAR T细胞实现意向治疗白血病缓解

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
PubMed 文献 · Blood · 2017-04-13

一项针对45例复发或难治性B系急性淋巴细胞白血病儿童和年轻成人的1期试验,使用CD4/CD8组成确定、CAR表达均一且效应分化有限的CD19 CAR产品。最大耐受剂量为每公斤10^6个CAR T细胞,无意向性治疗MRD阴性缓解率为89%,23%患者出现可逆性重度细胞因子释放综合征和/或可逆性重度神经毒性。

要点

  • 最大耐受剂量为每公斤10^6个CAR T细胞,无归因于产品毒性的死亡或脑水肿。
  • 意向治疗MRD阴性缓解率为89%,接受产品者93%,接受氟达拉滨和环磷酰胺清淋者100%。
  • 23%患者发生可逆性重度细胞因子释放综合征和/或可逆性重度神经毒性。

核心结论

  • 制造组成确定的CD19 CAR T细胞可确定最佳细胞剂量,在该预后不佳的患者队列中具有高效抗肿瘤活性和可耐受的不良反应特征。

研究设计与样本

  • 1期试验纳入45例复发或难治性B系急性淋巴细胞白血病儿童和年轻成人,使用CD4/CD8组成确定、CAR表达均一且效应分化有限的CD19 CAR产品,试验注册号NCT02028455。

主要发现

  • 符合所有规定规格的产品出现在93%的入组患者中。
  • 最大耐受剂量为每公斤10^6个CAR T细胞,无归因于产品毒性的死亡或脑水肿事件。
  • 本1期研究的总体意向治疗微小残留病阴性(MRD-)缓解率为89%。
  • 接受CAR T细胞产品的患者MRD-缓解率为93%,接受氟达拉滨和环磷酰胺清淋的患者亚组为100%。
  • 23%的患者发生可逆性重度细胞因子释放综合征和/或可逆性重度神经毒性。

关键数值与推荐

  • 符合所有规定规格的产品出现在93%的入组患者中。
  • 最大耐受剂量为每公斤10^6个CAR T细胞。
  • 总体意向治疗MRD-缓解率为89%,接受产品者93%,接受氟达拉滨和环磷酰胺清淋者100%。
  • 23%患者发生可逆性重度细胞因子释放综合征和/或可逆性重度神经毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity resulting from transduction of undefined T-cell mixtures, variability of transgene expression, and terminal differentiation of cells at the end of culture. A phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia was conducted using a CD19 CAR product of defined CD4/CD8 composition, uniform CAR expression, and limited effector differentiation. Products meeting all defined specifications occurred in 93% of enrolled patients. The maximum tolerated dose was 106 CAR T cells per kg, and there were no deaths or instances of cerebral edema attributable to product toxicity. The overall intent-to-treat minimal residual disease-negative (MRD-) remission rate for this phase 1 study was 89%. The MRD- remission rate was 93% in patients who received a CAR T-cell product and 100% in the subset of patients who received fludarabine and cyclophosphamide lymphodepletion. Twenty-three percent of patients developed reversible severe cytokine release syndrome and/or reversible severe neurotoxicity. These data demonstrate that manufacturing a defined-composition CD19 CAR T cell identifies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profile in a cohort of patients with an otherwise poor prognosis. This trial was registered at www.clinicaltrials.gov as #NCT02028455.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017. PMID: 28408462. doi:10.1182/blood-2017-02-769208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。